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Introduction 
The surgical option which should be reserved for patients with BRCA1/2 mutation and breast 
cancer diagnosis is still debated. For women without BRCA mutation, breast-conserving therapy 
(BCT), i.e. breast-conserving surgery (BCS) followed by radiation therapy (RT), is the treatment of 
choice as it offers similar survival to that of unilateral mastectomy1-2. However, after a breast 
cancer diagnosis in BRCA-mutation carriers, the optimal local management remains a matter of 
debate. Initial concerns about the potential harmful effects of radiation therapy after BCS in patients 
with mutated BRCA turned out to be unsubstantiated3-4 and several studies support the conservative 
surgery as a reasonable option. However, several aspects should be considered before the surgical 
decision-making: the risk of ipsilateral breast recurrence (IBR), the risk of contralateral breast 
cancer (CBC), the potential survival benefit of prophylactic mastectomy, and the possible risk 
factors that could either increase or decrease the risk for IBR or CBC. This aspects may be helpful 
to identify a goup of patients candidates for more aggressive treatments.  
 
Is the BCT option worse than unilateral mastectomy? 
Studies comparing risk of ipsilateral breast cancer recurrence (IBR) following BCT between 
carriers and non-carriers are largely retrospective and have generated conflicting results. Several 
studies conclude that breast conservative therapy does not increase the risk for IBR in BRCA 
mutation carriers compared to non-carriers, however, an increased risk for IBR in carriers was 
observed in studies with longer follow-up. A recent meta-analysis5, including 526 BRCA mutation 
carriers and 2320 controls, analysing ten studies (6 cohort and 4 case-control), demonstrated no 
significant difference in the rates of IBR for BRCA-mutation and controls (17.3 % and 11 % 
respectively, RR 1.45, 95 % CI 0.98–2.14, p value = 0.07) (Table 1).  
 
Table 1: Risk for IBR in BRCA mutation carriers versus controls5 
Cohort studies Risk Ratio (95% IC) 
Brekelmans 20076 0.61 [0.33, 1.11] 
Chappuis 20007 0.97 [0.22, 4.15] 
El-Tamer 20048 3.22 [1.15, 9.01] 
Haffty 20029 2.15 [1.13, 4.07] 
Robson 199810 0.46 [0.06, 3.34] 
Robson 200411 1.57 [0.73, 6.36] 
Subtotal (95% IC) 1.32 [0.70, 2.46] 
Case-control studies  
Eccles 200112 0.69 [0.30, 1.58] 
Garcia-Etienne 200913 4.50 [1.32, 15.35] 
Kirova 201014 1.90 [1.22, 2.97] 
Pierce 200615 1.51 [0.89, 2.56] 
Subtotal (95% IC)   1.60 [0.94, 2.56] 
Total (95% IC) 1.45 [0.98, 2.14] 
 Stratifying patients according to follow up the AA confirm no significant difference in local 
recurrence between carriers and controls in studies with a median follow-up <7 years (6 studies: 
1212 patients, local recurrence 11.7% carriers versus 8.9% controls, RR 1.38, 95% CI 0.53-3.60, p 
= 0.51); however, in studies with longer follow-up (5 studies, 1634 patients) the incidence of local 
recurrence among BRCA mutation carriers increased substantially to 23.7% as compared to 15.9% 
among controls (RR 1.51, 95% CI 1.15 -1.98, p < 0.003). This occurrence may be explained by a 
higher risk for new primary cancers in carriers, since their mutation-related risks continue to affect 
the residual breast tissue after removal of the first lesion. No overall survival (OS) difference was 
observed between BRCA mutated patients and controls who choosed to undergo breast-conserving 
surgery. 
As to the risk for IBR in BRCA mutation carriers after mastectomy versus BCT few data are 
available in literature. Patients who underwent BCT had higher risk for IBR than patients with 
mastectomy with a cumulative estimated risk of 23.5% vs. 5.5%, respectively, at 15 years 
(p<0.0001). However, no significant difference in breast-cancer specific or overall survival was 
observed by local treatment type at 15 years. Breast cancer-specific survivals with BCT were 93.5% 
vs. 92.8 with mastectomy (p=0.85). Overall survivals with BCT group were 91.8% and 89.8% with 
mastectomy (p=0.73)3. When the pattern of IBR in each group is analyzed, IBRs in BCT-group are 
mostly new primary cancers while in mastectomy-group they are true recurrences. The lack of 
survival difference between mastectomy and BCT may reflect the differences in the type of IBRs 
between the two groups since new primary cancers have biologically less aggressive phenotype 
than true recurrences. A recent study  comparing breast-conserving therapy and mastectomy in 
BRCA1/2 mutation carriers reaches the same conclusions. Compared to mastectomy, BCT is 
associated with an increased risk of IBR also in multivariable analysis adjusting for tumor stage, 
age, and use of adjuvant chemotherapy (HR 2.9; CI 1.1–7.8). The cumulative incidence of LR in the 
BCT group was 32 % after 15 years versus 9% in the Mastectomy group, but there were no 
significant differences between BCT and mastectomy for OS, breast cancer death, or distant 
recurrence. Following mastectomy, local recurrences (LR) were seen in the first 5 years after breast 
cancer diagnosis, while following BCT, the rate of LR continued to be high also after the first 5 
years (Table 2)16. 
 
Table 2:  Five, ten, and fifteen-year cumulative incidences (%) of death of any cause, breast cancer 
death, distant recurrence, and local recurrence as first recurrence (LR) split on mastectomy (M) or 




distant recurrence breast cancer 
death 
death of any cause 
 M BCT M BCT M BCT M BCT 
Adjusted*HR 
(95% IC) 
1.0 2.9  
[1.1-7.8] 
1.0 1.8  
[0.9-3.5] 
1.0 1.6  
[0.8-3.3] 
1.0 1.4  
[0.8-2.5] 
         
* Adjusted for TNM stage, age at diagnosis, and use of (neo)adjuvant chemotherapy 
 
The potential risk factors for IBR after BCT in BRCA-mutation carriers were extensively studied. 
Two factors, supported by a moderate level of evidence, were found to be protective against IBR: 
the use of adjuvant chemotherapy (RR 0.51, 95 % CI 0.31–0.84), and oophorectomy (RR 0.42, 95 
 % CI 0.22–0.81)5. In the same meta-analysis the use of adjuvant tamoxifen was not significantly 
associated with IBR (level of evidence: moderate), even if another study claims the protective effect 
of Tamoxifen independent from being mutation carrier or not3.  
 
Does contralateral prophylactic mastectomy (CPM) offer any additional advantages 
compared to BCT or unilateral mastectomy? 
Patients with BRCA mutation had a higher risk for contralateral breast cancer (CBC) compared 
with non carriers (RR 3.56, 95 % CI 2.50–5.08, p value < 0.001) and BRCA1-mutation carriers had 
an increased risk for CBC compared to BRCA2-mutation carriers. Pooled rates of CBC in a meta-
analysis of 11 studies (7 cohort and 4 case-control), including 807 carriers and 3163 controls were 
23.7% and 6.8% respectively (RR 3.56, 95% CI 2.50-5.08, p < 0.001) (Table 3)5.  
 
Table 3: risk for CBC: BRCA-mutation carriers versus non-carriers5 
 
Cohort studies Risk Ratio (95% 
IC) 
Brekelmans 20076 3.54 [2.28, 5.49] 
Chappuis 20007 7.97 [1.39, 45.81] 
El-Tamer 20048 1.74 [0.98, 3.11] 
Haffty 20029 4.77 [1.86, 12.24] 
Robson 199810 4.88 [1.89, 12.58] 
Robson 200411 3.51 [2.05, 6.01] 
Stoppa-Lyonnet 200017 0.89 [0.39, 2.04] 
Subtotal (95% IC) 2.90 [1.85, 4.53] 
Case-control studies  
Eccles 200112 3.60 [2.15, 6.03] 
Garcia-Etienne 200913 15.0 [1.79, 125.57] 
Kirova 201014 3.67 [2.07, 6.48] 
Pierce 200615 8.34 [4.45, 15.63] 
Subtotal (95% IC)   5.0 [2.97, 8.40] 
Total (95% IC) 3.56 [2.50, 5.08] 
 
Among 7 studies investigating the risk difference between BRCA1 and BRCA2 carriers (1,532 
BRCA1-mutation carriers, 950 BRCA2- mutation carriers), the rates of CBC were 21.1% and 
15.1%, respectively (RR 1.42, 95% CI 1.01-1.95, p <0.04)5. Another meta-analysis18 yielded similar 
results with a cumulative 5-years risk of CBC for BRCA1 and BRCA2 mutation carriers of 15% 
and 9%, respectively. The risk increases with  time after the first breast cancer diagnosis, growing at 
10-years up to 27% and 19%, respectively. In contrast, the 5-years cumulative risk was substantially 
lower in non-BRCA carriers (3%) and remained the same over the subsequent years (5% at 10 
years). Bilateral mastectomy is intended to prevent CBC in BRCA mutation carriers. However, no 
difference in survival was found if a contralateral prophylactic mastectomy was performed or not, 
but specific studies are small and the median follow-up relatively short5. Two studies6-19 on breast 
cancer specific survival (BCSS), with a median follow-up time of 4.3 and 3.4 years respectively 
showed no difference between patients with BRCA-mutation who underwent contralateral 
prophylactic mastectomy and patients with BRCA-mutation who did not undergo prophylactic 
 mastectomy (HR 0.78, 95 % CI 0.44–1.39, p value = 0.40). Only one study19 on overall survival 
(OS), achieved a significant difference between two groups with 94% OS for the prophylactic 
mastectomy group versus 77% for the non-prophylactic mastectomy group (p value = 0.03). 
However, when adjusted for other factor as prophylactic oophorectomy women in the first group 
did not show a significantly better survival than those in the second group (HR 0.35, p value = 
0.14). The largest study with the longest follow-up on this topic was reported at the American 
Society of Clinical Oncology Annual meeting in 2013. A statistically significant improved survival 
in patients who underwent prophylactic mastectomy compared with those without mastectomy (10 
year OS 90% versus 80%, respectively) was reported20. However an important bias was that more 
patients in the prophylactic mastectomy group received adjuvant chemotherapy. This difference 
could result in improved OS, especially considering the greater sensitivity to chemotherapy of 
BRCA-associated breast cancers. Therefore, the question whether contralateral prophylactic 
mastectomy confers a survival benefit in carriers with breast cancer still remains open. Metcalfe et 
al. published a recent retrospective analysis with the aim to compare the survival rates of women 
with BRCA associated breast cancer who did and did not undergo mastectomy of the contralateral 
breast21. They conclude that BRCA mutated women treated for early stage breast cancer with 
bilateral mastectomy are less likely to die from breast cancer than women treated with unilateral 
mastectomy. At 20 years the survival rate for women who had contralateral mastectomy was 88% 
versus 66% for those who did not. After controlling for age at diagnosis, treatment, and other 
prognostic features, contralateral prophylactic mastectomy was associated with a 48% reduction in 
death from breast cancer (hazard ratio 0.52, 95% IC 0.29-0.93; P=0.03). Authors conclude 
predicting that of 100 women treated with contralateral mastectomy, 87 will be alive at 20 years 
compared with 66 of 100 women treated with unilateral mastectomy.  
CBC after a first breast tumor in BRCA mutated patients can be attributed to genetic predisposition, 
but it can also be related to the same external factors that cause CBC among non-carriers, including 
hormonal and reproductive factors. Analyzing the risk factors for CBC in BRCA-mutation carriers, 
in they recent meta-analysis, Velakis et al. identify two factors consistently associated with 
decreased risk: oophorectomy (RR 0.52, 95 % CI 0.37–0.74) and increased age at diagnosis (a 
cumulative HR is not defined in the meta-analysis). Metcalfe et al.22 demonstrated that CBC risk is 
higher for women diagnosed with first breast cancer at younger ages: diagnosis in women <50 years 
old was associated with increased risk of CBC at 15 years compared to diagnosis at >50 years 
(37.6% versus 16.8%, p <0.001). Similarly, in an previous study by Graeser et al.23, age >50 years 
at diagnosis was associated with decreased risk of CBC in BRCA1 patients. One additional factor 
that could reduced the risk for CBC is the use of adjuvant tamoxifen (RR 0.57, 95 % CI 0.43–0.75). 
This protective effect seems to be stronger in women who did not undergo oophorectomy (RR 0.42, 
95 % CI 0.27–0.63). The use of adjuvant chemotherapy did not alter the risk for CBC (RR 0.90, 95 
% CI 0.66–1.22) 5.  
 
Are there any risk factors that identify subgroups of patients that will gain more benefit with 
more aggressive surgical management? 
For higher-risk groups of BRCA mutated patients, a more-aggressive surgical approach may be 
preferable. However, ER tumor status, stage of the index lesion, and individual patient preferences 
should all be considered in the surgical decision-making process. As mentioned above, the use of 
adjuvant chemotherapy and performing oophorectomy are associated with a 50% decreased risk for 
IBR. As a result, in carriers who have not undergone oophorectomy, a more aggressive surgical 
approach (unilateral mastectomy or unilateral therapeutic mastectomy with concomitant 
 contralateral prophylactic mastectomy) might be more appropriate. When considering the risk for 
CBC, three risk factors were associated with significantly decreased risk: the use of adjuvant 
tamoxifen, performing oophorectomy and older age at first breast cancer diagnosis. As a result, 
younger patients that have not undergone oophorectomy and have not received adjuvant tamoxifen 
might constitute a subgroup of patients that might benefit from a more aggressive surgical 
approach. Also considering that BRCA1-mutation carriers have an increased risk for CBC 
compared to BRCA2-mutation carriers, available data suggest that young patients with BRCA1-
associated breast cancers would potentially derive the most benefit from an aggressive surgical 
approach. On the other end older patients with BRCA2-associated ER positive breast cancer may 
achieve adequate local control and take an acceptable risk of CBC with a less-aggressive surgical 
approach followed by anti-estrogen therapy. Prophylactic oophorectomy to reduce the risk of 
ovarian cancer should always be considered. 
 
Nipple sparing Mastectomy in BRCA mutated patients and Patients satisfaction after 
prophylactic mastectomy  
Contemporary therapeutic and prophylactic surgical management options include total 
mastectomy, skin-sparing mastectomy (SSM) and nipple sparing mastectomy (NSM), with the latter 
two surgical options having superior cosmetic results. For women with BRCA mutations candidate 
to mastectomy, preservation of the nipple-areola complex (NAC) may be highly important due to 
the generally younger age at time of surgery. In comparison to skin-sparing mastectomy, the nipple-
sparing approach may allow a superior cosmetic outcome and higher levels of patient satisfaction24. 
Several studies have shown that preservation of the NAC is safe with no increased risk of local 
recurrence in women with sporadic breast cancer25. The role of NSM in BRCA mutation carriers 
has not been well clarified, limited data assessing oncologic outcomes in BRCA mutation carriers 
are currently available. An important concern regarding NSM in women with a BRCA mutation is if 
this surgical procedure is oncologically safe, because the retained breast ductal epithelium carrying 
the mutation, may be at risk for breast cancer development. Recent studies demonstrate no higher 
rates of tumor involvement of the nipple in BRCA-positive patients undergoing NSM and 
immediate reconstruction, low local–regional recurrence, and low development of new cancers26.  
There is a low probability of nipple involvement by premalignant or malignant lesions at time of 
prophylactic mastectomy in BRCA mutation carriers. Terminal duct lobular units (TDLUs) found 
within the NAC would provide a possible nidus for subsequent development of cancer; TDLUs was 
found in 9-25% of nipple specimens27, but the significance of this for long-term risk is unknown. 
The rate of tumor involvement of the NAC in studies with significant numbers of BRCA-positive 
patients in their cohorts undergoing prophylactic SSM (with NAC excision) is 0–5.6 %28-29. One 
analysis of NAC specimens exclusively in BRCA-positive patients undergoing SSM for 
prophylactic indications showed no in situ or invasive cancer in any cases30.  Another  recent study 
whit specific analysis of NAC specimens in BRCA-mutated patients showed minimal rates of tumor 
involvement after either prophylactic or therapeutic mastectomy26. Several retrospective studies 
have shown on the average 18% nipple involvement by tumor in therapeutic mastectomy specimen 
from the general population;  in BRCA mutated patients the rate is comparable (19%)31. The rate of 
NAC involvement is strongly influenced by the patient selection and intraoperative evaluation of 
the tissue behind the NAC to try and minimize risk. In multivariate models, tumor size, stage, and 
tumor distance to nipple were predictors for occult nipple-areola involvement32-33. 
Concerning the oncological safety, several studies of nipple sparing mastectomy in high-risk 
woman have shown a low rate of development of new primary carcinoma in residual breast tissue34. 
 Data are limited regarding local recurrence after therapeutic mastectomy in BRCA mutation 
carriers, the rate seems to be similar to the cohort of non-mutation carriers with median follow-up 
of 50 months6. A recent study26 reports the largest series of BRCA positive patients who underwent 
NSM and specifically examines oncologic outcomes in this group of patients: at 4-year follow-up 
equivalent safety has been shown in BRCA carriers and in controls. NSM is an acceptable option 
for patients with BRCA mutations, with no evidence of compromise to oncological safety at short-
term follow-up35. Recently published studies have demonstrated oncologic outcomes after NSM 
comparable to those after skin-sparing mastectomy, with locoregional recurrence as low as 2% at 3-
year follow-up36. 
In patients candidates to conservative surgery for unilateral breast cancer, the decision to perform a 
contralateral prophylactic mastectomy (CPM) is more difficult to take. However, in general, women 
with prophylactic breast surgery, report to be highly satisfied with their decision, and believe that 
surgery greatly reduced the risk of developing cancer37-38. Frost has shown that positive outcomes 
following surgery include decreased emotional concern about developing breast cancer (75%) and 
generally favorable psychological and social outcomes. Borgen et al39 found that only 5% of 
respondents had significant regrets after prophylactic mastectomy. The majority of women reported 
no change or improvement of their emotional mood, reduction of the level of stress 
and no substantial change in sexual relationships and in perception of their woman’s image40. 
Depression of mood can occur after surgery, but it’s more likely attributable to the general 
circumstance of having cancer than to surgery and rarely requires drug therapy. Focusing on 
cosmetic results, most of women reported highly/moderate satisfaction. A large percentage of 
women lost touch sensitivity, but most of them reported favorable effects or no change in self-
esteem, satisfaction with body appearance, feelings of femininity, sexual relationships, level of 
stress in life, and overall emotional stability38. Only few women were negative in their responses 
reporting a change for the worse of their female image. Frost40 suggests that the basis for the 
difference in satisfaction with prophylactic mastectomy may be the possible complications 
associated with surgery as implant failure, esthetic implant concerns and silicone anxiety. The need 
for a reoperation was associated with dissatisfaction. Paradoxically, more women with 
subcutaneous mastectomy than women with simple mastectomy were dissatisfied with their 
decision and would not choose mastectomy again. In other series, subcutaneous mastectomy was 
performed more commonly than simple mastectomy; authors reported a small number of surgical 
complication and women reported the highest level of satisfaction with nipple sparing mastectomy 
and immediate reconstruction.  Any adequate discussion and counseling of BRCA mutated patients 
with unilateral breast cancer about the possible surgical management should also include the 
psychosocial and aesthetic dimension of each surgical intervention. 
 
Mastectomy and radiotherapy 
When considering the best surgical approach for the patient, it’s important to take into account the 
impact of adjuvant radiotherapy on the surgical outcomes following mastectomy and immediate 
or delayed breast reconstruction.  Post mastectomy radiation therapy (PMRT) following breast 
reconstruction may compromise aesthetic outcomes as well as increase complication rates for both 
implant (expanders or implants) and autologous reconstructions. The main complication of implant-
based reconstruction is the fibroproliferation of the capsular tissue around the breast implant with 
consequent capsular contracture, which leads to poor expansion due to the stiffening of the tissues. 
The breast deformation and pain, often require additional surgery and sometimes lead to 
reconstructive failure. Despite improvements in surgical technique and device manufacturing, 
 complications requiring reoperation were 37% and reconstructive failure was 16.8% in the study of 
Bassim el-sabawi  at al41.  Strategies to reduce the incidence of such complication are mainly 
focused on the timing of PMRT relative to the type of device. If no postmastectomy radiotherapy is 
planned, skin-sparing mastectomy or nipple-sparing mastectomy with immediate reconstruction 
involving implants is preferable. If post mastectomy radiotherapy is planned, the physician should 
consider the advantages and disadvantages of immediate versus delayed reconstruction and the type 
of device (expanders or implants). The second stage of breast reconstruction can be performed 
before or after post-mastectomy radiation therapy, but this strategy cannot by applied when 
performing NSM with one-stage reconstruction and immediate implant placement at the time of 
mastectomy. In the setting of immediate reconstruction, PMRT to permanent implants seems to be 
associated with a lower rate of reconstructive failure as compared to tissue expanders (18.8% vs. 
14.7%)41. In a study focused on the timing of PMRT, Cordeiro et al. compared 94 patients that had 
PMRT in the setting of tissue expanders to 210 patients that had PMRT in the setting of permanent 
implants42. The reconstructive failure rates were 18.1% with PMRT to tissue expanders and 12.4% 
with PMRT to permanent implants. The group with the irradiated permanent implants had 
significantly more Grade III and IV capsular contracture rates (44.6% v. 15.9%). In a similar study, 
Nava et al. reported reconstructive failures in 40% of women subjected to PMRT in the setting of 
tissue expanders versus 6.4% in the setting of permanent implants43. 
Another important issue is the prior chest or breast irradiation before mastectomy. Prior 
radiotherapy may increase the risk of complications after NSM and immediate reconstruction, 
including skin and nipple necrosis as frequent as 20 %44. Prior RT is not an absolute 
contraindication to NSM, although complication rates are higher in irradiated breasts, 
reconstruction failure and nipple/areola necrosis is infrequent45. However, before performing a BCS 
followed by RT it’s important to consider that prior radiotherapy increases the risk of complications 
in a possible subsequent NSM with immediate breast reconstruction.  
Conclusions 
Clinical guidelines regarding the surgical management of unilateral breast cancer for BRCA 
mutated patients are still missing. Mutation carriers with unilateral breast cancer need to be 
discussed by a multidisciplinary team and the counseling should be managed on a case-by-case 
basis. The evaluation should include several issues, namely: the current evidence of adequate 
oncological safety of BCT in BRCA mutated patients, the increased risk for CBC especially in 
BRCA1 carriers; the feasibility on NSM with a greater patient’s satisfaction for cosmetic results 
with no evidence of compromised oncological safety at short-term follow-up and finally the 
awareness that breast radiotherapy might increase the risk of complications in a possible subsequent 
mastectomy with immediate breast reconstruction.  
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